News
PureTech Announces Annual Results for Year Ended December 31, 2024
BOSTON, April 30, 2025--PureTech Announces Annual Results for Year Ended December 31, 2024
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/073b0b5860090c4b8258bc4061571d66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zx43XhKOMOwCo.26vKqxOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/073b0b5860090c4b8258bc4061571d66","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Lucpvep8NazuKLldxSVsHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/073b0b5860090c4b8258bc4061571d66","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million","length":397,"tagName":"p","attribs":{}},{"type":"text","content":"Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 2027","length":302,"tagName":"p","attribs":{}},{"type":"text","content":"As of March 31, 2025, PureTech level cash, cash equivalents and short-term investments were $339.1 million5","length":107,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, April 30, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") today announces its results for the year ended December 31, 2024, as well as its cash balance as of the first quarter ended March 31, 2025. The following information represents select highlights from the full UK Annual Report and Accounts, except as noted herein, a portion of which will be filed as an exhibit to PureTech’s Annu...